Uploaded June 2024 | Updated November 2026, 8 hours ago
For his WALS talk, Garcia will discuss technology advancements that have allowed for high-throughput quantitative mass spectrometry analyses of histone post-translational modification sites (PTMs) and chromatin structure, and how investigators are applying these methods to understand epigenetic reprogramming found in malignant peripheral nerve sheath tumors (MPNSTs). MPNST is an aggressive sarcoma with recurrent loss of function alterations in polycomb-repressive complex 2 (PRC2), a histone-modifying complex involved in transcriptional silencing.
For more information go to oir.nih.gov/wals
For his WALS talk, Garcia will discuss technology advancements that have allowed for high-throughput quantitative mass spectrometry analyses of histone post-translational modification sites (PTMs) and chromatin structure, and how investigators are applying these methods to understand epigenetic reprogramming found in malignant peripheral nerve sheath tumors (MPNSTs). MPNST is an aggressive sarcoma with recurrent loss of function alterations in polycomb-repressive complex 2 (PRC2), a histone-modifying complex involved in transcriptional silencing.
For more information go to oir.nih.gov/wals





![Harnessing African Genomic Variations to Improve Health and Equity Globally
Air date: Wednesday, September 14, 2022, 2PM
Description: NIH Director’s Wednesday Afternoon Lecture Series [WALS ]
Prof Ambroise Wonkam is a professor of Genetic Medicine, and Director of the McKusick-Nathans Institute, and Department of Genetic Medicine. After an MD training from the Faculty of Medicine and Biomedical Sciences, University of Yaoundé I (Cameroon), he completed a thesis in Medical Sciences, University of Geneva (Switzerland) and a Ph.D. in Human Genetics (University of Cape Town, South Africa). Other salient aspects of Prof Wonkam’s background include his education as a medical geneticist at a highly reputable genetics department in Geneva (Switzerland). He subsequently practices medical genetics in both European and African contexts.
African genomes harbor millions of uncaptured variants accumulated over 300,000 years of modern humans evolutionary history, with successive waves of admixture, migration, and natural selection combining with extensive ecological diversity to create a broad and exceptional genomic complexity. Therefore to embrace the prospects of accurately diagnosing thousands of monogenic conditions, predicting disease risks for complex traits or diseases, tailoring treatment to individuals pharmacogenetic profiles, and potentially curing some diseases, research into African genomic variation is a scientific imperative.
For more information go to https://oir.nih.gov/wals
Author: Ambroise Wonkam, M.D., Ph.D., Hopkins Medicine
Permanent link: https://videocast.nih.gov/watch=45982 Harnessing African Genomic Variations to Improve Health and Equity Globally](https://i.ytimg.com/vi/bNuUluhiozI/mqdefault.jpg)

![Mutant p53 Activities in Mouse Tumor Models
Air date: Wednesday, December 7, 2022, 3PM
Description: NIH Director’s Wednesday Afternoon Lecture Series [WALS]
Margaret Pittman Lecture
This is the annual WALS–Pittman lecture, but rescheduled from March 2022. Guillermina (Gigi) Lozano is a renowned geneticist recognized for her studies of the p53 tumor suppressor pathway. This pathway is undermined in a large percent of human cancers via mutations and deletions of p53. Her laboratory identified a transcriptional activation function for p53. Using mouse models, her team characterized the physiological importance of Mdm2 and Mdm4 proteins as potent inhibitors of p53. The Mdm proteins are over expressed in many cancers that lack p53 mutations presenting an alternate mechanism of eliminating p53 activity. Other mouse models inheriting the most common p53 mutations revealed gain-of-function phenotypes that drive metastases. Mutation of the p53 gene is a critical event in the elaboration of many tumors of diverse origin. The p53 protein is activated in response to DNA damage, serving as a checkpoint in the elimination or repair of cells with damaged DNA. Alterations in components of the p53 pathway, such as amplification of the Mdm2 gene, which encodes a p53 inhibitor, also contribute to tumorigenesis. The overall goal of my laboratory is to understand the signals that regulate the p53 pathway and the consequences of expressing wild-type or mutant p53.
For more information go to https://oir.nih.gov/wals
Author:
Guillermina Lozano, Ph.D., University of Texas MD Anderson Cancer Center
Permanent link: https://videocast.nih.gov/watch=46003 Mutant p53 Activities in Mouse Tumor Models](https://i.ytimg.com/vi/cAkliNT8CI0/mqdefault.jpg)


